Pelvic exenteration for recurrent rectal cancer: A single institution experience Rekürren Rektal Kanserlerde Pelvik Ekzantrasyon: Tek Merkez Deneyimi
Turkish Journal of Colorectal Disease, cilt.31, sa.1, ss.20-24, 2021 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 31 Sayı: 1
- Basım Tarihi: 2021
- Doi Numarası: 10.4274/tjcd.galenos.2020.2020-8-1
- Dergi Adı: Turkish Journal of Colorectal Disease
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.20-24
- Anahtar Kelimeler: Complication, Pelvic exenteration, Rectal cancer, Recurrence, Survival
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: Rectal cancer is an important cause of cancer-related deaths worldwide (1-2). Although rectal cancers can be diagnosed earlier nowadays due to the development of screening programmes, 18% of patients have a locally advanced stage at the time of diagnosis (3). Despite the improvements in total mesorectal excision and oncological treatments, the locoregional recurrence rates vary between 6-10% in rectal cancer patients (4-5). Method: The data of patients who underwent pelvic exenteration for recurrent rectal cancer in our clinic between January 2015 and December 2019 were retrospectively analysed. Results: It was found that the patients with lymphovascular invasion (LVI) and perineural invasion (PNI) showed statistically poor survival rates (p=0.038/0.022). Two of the patients had a positive surgical margin and two others had a positive radial margin. There was no statistically significant difference between surgical margin positivity and prognosis (p>0.05). The mean number of metastatic lymph nodes was 4.0 (0-12), and the total number of lymph nodes was 12.35 (2-27). There was no statistically significant difference between patients with lymph node metastasis in terms of survival (p=0.079). Seven of the patients (41.1%) received systemic treatment before the surgery. It was statistically determined that the patients who received this treatment showed better survival rates (p=0.045). Conclusion: It was found that pelvic exenteration had a positive effect on survival and local recurrence in recurrent rectal cancer, and that neoadjuvant therapy increased survival rates.